Molecular Partners
MOLN
5 hedge funds and large institutions have $17M invested in Molecular Partners in 2024 Q4 according to their latest regulatory filings, with funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 0 closing their positions.
306% more capital invested
Capital invested by funds: $4.2M → $17M (+$12.8M)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
6.56% more ownership
Funds ownership: 2.31% → 8.88% (+6.6%)
0% more funds holding
Funds holding: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$10M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$5.01M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$8.95K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$732 |
MOLN Hedge Fund Activity: Q4 2024 in Review
5 of the 7,605 institutional investors tracked by Wall St. Rank reported a position in Molecular Partners (MOLN) for Q4 2024, worth a combined $17M — up 306% from $4.2M a quarter earlier.
Fund positioning in MOLN was balanced in Q4 2024: 0 funds opened new positions, 0 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was Suvretta Capital Management, adding an estimated $10M. The largest seller was Morgan Stanley, cutting an estimated $732.
- 5 institutional investors held Molecular Partners (MOLN) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $17M of Molecular Partners stock for Q4 2024, up 306% quarter-over-quarter.
- 0 funds opened new Molecular Partners positions in Q4 2024 and 0 closed out.
- The largest Molecular Partners buyer in Q4 2024 was Suvretta Capital Management, an estimated $10M added.
- The largest Molecular Partners seller in Q4 2024 was Morgan Stanley, an estimated $732 sold.
Based on aggregated 13F filings for Q4 2024.